New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 18, 2013
13:21 EDTCEA, BCRX, ZNH, YUM, GSKBird-flu may add risks to China slowdown, Bloomberg says
China’s bird-flu outbreak is affecting businesses from restaurants to travel, according to Bloomberg, citing a note to investors this week from Goldman Sachs that said the outbreak “may suppress domestic consumption in the near term." Bloomberg outlined the potential on a number of publicly-traded companies, including Yum! Brands (YUM), China Southern Airlines (ZNH) and China Eastern Airlines (CEA). The Fly notes companies developing bird flu vaccines include BioCryst (BCRX) and Glaxo (GSK). Reference Link
News For YUM;BCRX;GSK;ZNH;CEA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
14:17 EDTGSKGlaxoSmithKline looking for buyers for Nicotinell business, AFR reports
GlaxoSmithKline is looking for a buyer for its Australian nicotine chewing gum business Nicotinell, according to the Australian Financial Review. Reference Link
10:01 EDTYUMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:07 EDTYUMYum! Brands downgraded to Neutral from Outperform at RW Baird
Subscribe for More Information
March 2, 2015
11:06 EDTYUMVisa, Accenture, Pizza Hut partner for 'connected car' commerce experience
Subscribe for More Information
07:04 EDTGSKIsis Pharmaceuticals earns $15M from GlaxoSmithKline for advancing ISIS-TTR Rx
Isis Pharmaceuticals (ISIS) announced that it has earned a $15M milestone payment from GSK (GSK) related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug Isis is developing with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $60 million in upfront and milestone payments for advancing ISIS-TTRRx. In addition, if GSK elects to exercise its option to exclusively license ISIS-TTRRx, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
06:28 EDTBCRXFujifilm CEO says 'ready' for large orders of Avigan drug for Ebola, WSJ reports
Fujifilm’s (FUJIY) Avigan drug, which has shown signs of efficacy against the Ebola virus, has drawn interest from about 20 countries, The Wall Street Journal reports, citing comments made by CEO Shigetaka Komori. The drug was developed by Toyama Chemical, a Fujifilm unit, and Komori said the company is ready for large orders. Other drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
February 27, 2015
13:24 EDTBCRXLiberia, U.S. begin ZMapp ebola trial
In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study may be expanded to test ZMapp against other treatments which may also include the following: Tekmira siRNA from Tekmira Pharmaceuticals (TKMR), Favipiravir from Toyama Chemical, BCX4430 from BioCryst (BCRX), and AVI-7537 from Sarepta (SRPT). The trial is expected to conclude in December 2016.
09:48 EDTYUMYum! Brands says Marco Consulting to withdraw proxy access shareholder proposal
Subscribe for More Information
February 26, 2015
06:53 EDTYUMKFC to test edible coffee cup in U.K., NY Times says
Subscribe for More Information
06:27 EDTYUMYum!'s Taco Bell signs franchise agreement with Astrapport Dining
Subscribe for More Information
February 25, 2015
12:13 EDTGSKGlaxoSmithKline sees Novartis transaction closing next week
Subscribe for More Information
11:24 EDTGSKGlaxoSmithKline announces return of alli to retail stores
Subscribe for More Information
February 23, 2015
13:33 EDTGSKRBS could name Howard Davies as chairman this week, FT reports
Royal Bank of Scotland (RBS) could name Howard Davies as its chairman as early as Thursday, when the bank reports its full-year results, the Financial Times reports. Davies is currently chairman of insurance business Phoenix Group and chairs Morgan Stanley's (MS) risk committee. Current RBS Chairman Philip Hampton is set to become GlaxoSmithKline's (GSK) chairman as early as this summer. Reference Link
11:17 EDTGSKFTC puts conditions on Novartis's proposed acquisition of GSK oncology drugs
According to the FTC, Global pharmaceutical company Novartis (NVS) has agreed to divest all assets related to its BRAF and MEK inhibitor drugs, currently in development, to Boulder, Colorado-based Array BioPharma (ARRY) to settle charges that Novartis’s $16B acquisition of GlaxoSmithKline’s (GSK) portfolio of cancer-treatment drugs would likely be anticompetitive...If the acquisition goes forward as proposed, Novartis would likely delay or terminate development of both its BRAF and MEK inhibitors, as well as the combination product. For that reason, Novartis’s acquisition of GSK’s portfolio of cancer-treatment drugs would likely cause significant competitive harm in the U.S. markets for both the BRAF and MEK inhibitors, ultimately raising prices for consumers and depriving them of potentially superior products. Under the terms of the proposed consent agreement, Novartis is required to provide transitional services to Array BioPharma to ensure that development of the BRAF and MEK inhibitors continues uninterrupted and that competition in BRAF and MEK inhibitor markets is not reduced. Reference Link
February 20, 2015
07:23 EDTGSKAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTGSKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
08:23 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
February 18, 2015
06:58 EDTBCRXBioCryst sees FY15 operating expenses $75M-$95M
Subscribe for More Information
06:57 EDTBCRXBioCryst reports Q4 EPS (16c), consensus (21c)
Reports Q4 revenue $5.4M, consensus $3.64M.
February 17, 2015
07:38 EDTGSKGlaxo replaces head of struggling U.S. drug unit, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use